Literature DB >> 29256112

Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.

Alimohammad Fatemi1, Ahmad Raeisi2, Zahra Sayedbonakdar3, Abbas Smiley4.   

Abstract

This study was conducted to assess the ability of the British Isles Lupus Assessment Group-2004 (BILAG-2004), the SLE Disease Activity Index-2K (SLEDAI-2K), the European Consensus Lupus Activity Measurement (ECLAM), and the Revised Systemic Lupus Activity Measure (SLAM-R) to detect the need to treatment change in daily clinical practice. One hundred and two patients with SLE were enrolled and followed up for 2 to 8 months and visited at least 3 times. Physician Global Assessment, BILAG-2004, SLEDAI-2K, SLAM-R, and ECLAM, were calculated in every visit. Treatment change, dependent variable, was categorized as decrease/no change vs. increase. The aforementioned indices, independent variables, were compared to learn their ability in predicting the treatment change. The probability of treatment change was measured by generalized linear-mixed effect model (GLMM) and generalized estimating equations (GEE). Adjusted odds ratios were calculated. Predictive power of indices was compared by area under the curve (AUC) in plots of sensitivity vs. 1-specificity and application of receiver operating characteristic curves (ROC). BILAG-2004 and SLEDAI-2K had substantial correlation with treatment change. Among different GLMM models, BILAG-2004 followed by SLEDAI-2K showed the highest associations with treatment change. Among various GEE models, similar findings were observed. Also, these 2 indices had the highest sensitivity (the largest AUC) towards treatment change; BILAG-2004 (AUC = 0.779, 95% CI = 0.710-0.848, p = 0.001) and SLEDAI-2K (AUC = 0.771, 95% CI = 0.698-0.843, p = 0.001). BILAG-2004 followed by SLEDAI-2K had the highest predictability of treatment change.

Entities:  

Keywords:  BILAG-2004; ECLAM; SLAM-R; SLEDAI; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 29256112     DOI: 10.1007/s10067-017-3949-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

Review 2.  Measurement of systemic lupus erythematosus activity in clinical research.

Authors:  M H Liang; S A Socher; W N Roberts; J M Esdaile
Journal:  Arthritis Rheum       Date:  1988-07

3.  Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.

Authors:  Erika Chang; Michal Abrahamowicz; Diane Ferland; Paul R Fortin
Journal:  J Clin Epidemiol       Date:  2002-05       Impact factor: 6.437

Review 4.  How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?

Authors:  Inam Haq; D A Isenberg
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-04       Impact factor: 4.098

5.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

6.  Activity criteria in systemic lupus erythematosus.

Authors:  S Bombardieri; C Vitali; L Caponi; L Manca; W Bencivelli
Journal:  Clin Exp Rheumatol       Date:  1994 Nov-Dec       Impact factor: 4.473

7.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study.

Authors:  M Petri; M Genovese; E Engle; M Hochberg
Journal:  Arthritis Rheum       Date:  1991-08

8.  Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.

Authors:  D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; C Bombardier; D Isenberg; K Kalunian; M H Liang; P Maddison; O Nived
Journal:  J Rheumatol       Date:  1994-08       Impact factor: 4.666

Review 9.  Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.

Authors:  Jamal Mikdashi; Ola Nived
Journal:  Arthritis Res Ther       Date:  2015-07-20       Impact factor: 5.156

10.  British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.